1. Introduction {#sec1}
===============

Dysphagia was one of the most common sequelae after stroke. The incidence reached 81% \[[@B1]\]. There were many complications in dysphagia, such as cacotrophy \[[@B2]\], dehydration, aspiration, and pneumonia \[[@B3]\]. Those complications improve the morbidity, mortality, the rehabilitation, and the quality of life of the patients. So the medication and intervention time are very important for recovery. Acupuncture was an effective method and more and more welcomed and applied clinically \[[@B4]\]. There were many studies \[[@B5]--[@B7]\] about the acupuncture for treatment of dysphagia after stroke internationally, including the scalp acupuncture, nape needle, auricular needling, or combing with other methods.

Though, there were some systematic reviews focusing on the acupuncture for treatment of dysphagia in stroke. There was lack of higher quality research or the positive conclusion could not be obtained. Thus, the inclusion and exclusion criteria were formulated after integrating the previous relevant reports. And the studies using single blind method were pooled to be analysed alone.

2. Method and Data {#sec2}
==================

The criterion of systematic review was published in the Cochrane Collaboration which was available on <http://handbook.cochrane.org/>.

2.1. Type of Studies {#sec2.1}
--------------------

All articles were included that reported an RCT in patients with dysphagia after stoke. And the animal experiments were not inclusive.

2.2. Participants {#sec2.2}
-----------------

All the patients should conform to the explicit clinical diagnosis criteria of stroke and dysphagia. They should meet the following diagnosis of stroke: (1) the diagnostic criterion of the Fourth National Conference on cerebrovascular diseases in 1994 or the revised diagnostic criterion in 1995 or 1996; (2) the revised "Various Types of Cerebrovascular Disease Diagnosis Points" of The Fourth National Conference on cerebrovascular diseases of Chinese Medicine Association; (3) the "Chinese Cerebrovascular Disease Prevention And Treatment Guidelines (Try Out)" established by Neurology Branch of Chinese Medical Association according to the 2005 or 2007 Disease Control Division; (4) 1996 Chinese Medicine Internal Medicine Association "criterion for evaluating curative effect of apoplexy"; (5) the guidelines for diagnosis and treatment of acute ischemic stroke composed by cerebrovascular branch of Neurology of Chinese Medical Association; (6) the guidelines for diagnosis and treatment of acute ischemic stroke in China 2010 Edition; (7) National Institutes of Health Stroke Scale (NIHSS) \[[@B8], [@B9]\]; (8) the therapeutic efficacy evaluation standard of TCM diagnosis for stroke; (9) confirmed by head CT or MRI and other imaging methods for stroke; (10) Summary of the Sixth National Conference on cerebrovascular diseases.

2.3. Interventions {#sec2.3}
------------------

For the intervention in acupuncture group, acupuncture alone or combined with other interventions was all included, such as the rehabilitation training, swallowing therapeutic apparatus, swallowing training, and electrical stimulation. There was no distinction for the acupuncture manipulation, acupoint, stimulation intensity, and course of treatment. It is available for blank control group, drugs, or rehabilitation training in control group.

2.4. Outcome Measurement {#sec2.4}
------------------------

The clinical symptoms had obviously improved with specific evaluation criteria such as the (1) Watian Swallowing Test (WST) \[[@B10]\]; (2) Standardized Swallowing Assessment (SSA) \[[@B11]\]; (3) Ichiro Fujishima Rating Scale (IFRS) \[[@B12]\]; (4) Caiteng 7 Rank for dysphagia \[[@B13]\] or with using the objective index as the efficacy evaluation criterion, such as (1) video-fluoroscopic swallowing study \[[@B14]\]; (2) endoscopic evaluation of swallowing \[[@B15]\]; (3) fluorescence barium swallowing radiography score \[[@B16]\] which were recognized as swallowing assessment.

2.5. Information Sources and Search Strategy {#sec2.5}
--------------------------------------------

We search the following electronic databases from their inception until September 30, 2016: Science Citation Index (SCI), Plumbed, The Cochrane Library, EMBASE, Chinese National Knowledge Infrastructure (CNKI), WanFang Database, Chinese Scientific Journals Database (CSJD), and Chinese Biomedical Literature Database (CBM). The searching terms include "stroke", "apoplexy", "cerebral hemorrhage", "acicula", "acupuncture", "impaired swallowing", and "dysphagia".

2.6. Data Extraction {#sec2.6}
--------------------

Data were extracted independently by two authors (Qiuping Ye and Yu Xie) using a specifically designed data extracted form. The disagreements were solved by the third author\'s assistance (Junheng Shi) if necessary. The following information was extracted: (1) the first author, year of publication and the journal; (2) the research design; (3) the basic situation of the patients; (4) the inclusion and exclusion criteria; (5) the indicators of evaluation; and so on. After recording the reasons for exclusion, we got the flow diagram (see [Table 1](#tab1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}) including 71 studies \[[@B23]--[@B46]\].

2.7. Quality Assessment {#sec2.7}
-----------------------

The methodological quality of each study was assessed from the following aspects: (1) random sequence generation; (2) allocation concealment; (3) blinding of participants and personnel; (4) blinding of outcome assessment; (5) incomplete outcome data; (6) selective reporting; (7) other bias and judging from "yes (low risk)," "no (high risk)," or "unclear (information is insufficient to evaluate)" and reporting the risk of bias graph (Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

3. Result {#sec3}
=========

71 studies including 6010 patients were enrolled finally. There were 2991 participants in acupuncture group and 3019 participants in control group.

3.1. The Basic Characteristics {#sec3.1}
------------------------------

Two groups were compared statistically based on age, gender, duration, and degree of dysphagia. And the baseline was comparable. See [Table 2](#tab2){ref-type="table"}; 12 studies used the complete random and allocation concealment; 10 studies used the single blind method in the outcome assessment and statistics analysis. For the incomplete outcome data, 12 studies reported the fall off and exit of patients without any effect on the result; 17 studies mentioned the funding support, and not the others.

3.2. Data Analysis {#sec3.2}
------------------

RevMan 5.3.0 software was used for data analysis. And the different outcome assessment indicators were used to be classified and analysed. They were presented as risk ratio (RR) or mean difference (MD) with a 95% confidence interval.

3.3. Efficacy Rate {#sec3.3}
------------------

62 studies used the clinical efficacy rate as the evaluation indicator with the dichotomous data. So the risk ratio (RR) was used to show the result. We found the medium heterogeneity (*I*^2^ = 68%) after combining data. We could observe from the funnel plot that 3 studies \[[@B17], [@B31], [@B81]\] had deviated from the center line. After sensitivity analysis, we found that one study \[[@B17]\] considered the significantly effective result as recovery and the other as invalidation, which led to difference in results. At the same time, the intervention group of the two studies \[[@B31], [@B81]\] was treated with acupuncture combined with western medicine. And the curative effect was significantly higher than that of the control group. All the dots were equally distributed on both sides of the dashed line in the funnel plot with no publication bias after removing them ([Figure 4](#fig4){ref-type="fig"}). The moderate heterogeneity was found after remerging (*I*^2^ = 58%). So we chose the random effect model ([Figure 5](#fig5){ref-type="fig"}). The pooled analysis showed that the total rectangle was on the right of the equivalent line, which indicated the curative effect of acupuncture group was better than the control group (RR = 1.17, 95% CI: 1.13 1.21, *Z* = 9.08, and *P* \< 0.00001).

3.4. Standard Swallowing Assessment (SSA) {#sec3.4}
-----------------------------------------

There were 11 studies that used the SSA as the effective evaluation standard with the continuous data. The meta-analysis of them was showed in mean difference with high heterogeneity (*I*^2^ = 83%). So the random effect model was used ([Figure 6](#fig6){ref-type="fig"}). The figure showed that acupuncture group could lower the SSA cores (MD = 3.7, 95% CI: −4.93 −2.48, *Z* = 5.94, and *P* \< 0.00001).

3.5. Watian Swallowing Test {#sec3.5}
---------------------------

The Watian Swallowing Test was used in 24 studies; 9 of them used the dichotomous data. The risk ratio was selected to demonstrate the count data. The results ([Figure 7](#fig7){ref-type="fig"}) showed high heterogeneity (*I*^2^ = 87%). Hence the random effect model was used. And the rectangle was on the right of the equivalent line, which indicated that acupuncture group could improve the efficacy of dysphagia after stroke (RR = 1.25, 95% CI: 1.03 1.50, *Z* = 2.31, and *P* = 0.02 \< 0.05).

15 studies used the continuous data. And the mean difference was applied. The results showed that the heterogeneity of the merger was large. So we did the subgroup analysis according to the course of disease. Then the heterogeneity decreased from 95% to 67.4% ([Figure 8](#fig8){ref-type="fig"}). There was no publication bias in the funnel plot ([Figure 9](#fig9){ref-type="fig"}). Meanwhile, the pooled analysis showed that the acupuncture could lower the Watian Swallowing Test score (MD = 0.97, 95% CI: −1.11 −0.47, *Z* = 4.82, and *P* \< 0.00001).

3.6. Swallowing Functional Assessment {#sec3.6}
-------------------------------------

Among the included studies, 8 of them used the Swallowing Functional Assessment to evaluate the effectiveness of treatment with the continuous data. The result ([Figure 10](#fig10){ref-type="fig"}) exhibited the medium heterogeneity (*I*^2^ = 65%) with mean difference (MD). The result explained that acupuncture could improve the swallowing function with the random effect model (MD = 1.48, 95% CI: 1.18 1.79, *Z* = 9.59, and *P* \< 0.0001).

3.7. Swallowing Disorder Integral {#sec3.7}
---------------------------------

5 studies selected the swallowing disorder scoring as evaluated standard. The meta-analysis of the 5 dichotomous data sets showed that the heterogeneity decreased from 85% to 40% after removing one study \[[@B56]\]. The sensitivity analysis indicated that the heterogeneity might be the treatment course of this study which was longer than the others. We could see from the figure that the score of the control group was higher than the acupuncture group ([Figure 11](#fig11){ref-type="fig"}). It illustrated that acupuncture group was able to lower the swallowing disorder integral (MD = −0.71, 95% CI: −1.08 −0.33, *Z* = 3.7, and *P* = 0.0002).

3.8. Swallowing-Related Quality of Life (SWAL-QOL) {#sec3.8}
--------------------------------------------------

5 studies used the SWAL-QOL to express the Swallowing-Related Quality of Life before and after treatment. They all used the continuous data and mean difference to exhibit the results. The pooled analysis showed that rectangle was intersected with the equivalent line with high heterogeneity (*I*^2^ = 100%), which means nothing ([Figure 12](#fig12){ref-type="fig"}).

3.9. Activities of Daily Living (ADL) {#sec3.9}
-------------------------------------

2 studies \[[@B64], [@B77]\] used ADL to express the curative effect, two \[[@B27], [@B42]\] used the Barthel index, and the other one \[[@B50]\] used modified Barthel index. Among them, the activities of daily living before and after treatment were showed using the continuous data and mean difference. The meta-analysis indicted that acupuncture group obviously improved the activities of daily living of the patients with lower heterogeneity (*I*^2^ = 22%) ([Figure 13](#fig13){ref-type="fig"}). And it was 7.31 times as much as the control group (MD = 7.46, 95% CI: 5.49 9.47, *Z* = 7.31, and *P* \< 0.0001).

3.10. Caiteng 7 Rank (CT7R) {#sec3.10}
---------------------------

The CT7R was used in 2 studies \[[@B43], [@B46]\] with dichotomous and risk ratio. There was no heterogeneity (*I*^2^ = 0%) after combining the data with the fixed effect model ([Figure 14](#fig14){ref-type="fig"}), which indicated that the Caiteng 7 Rank scores of the acupuncture group were higher than the control group (RR = 1.22, 95% CI: 1.04 1.42, *Z* = 2.49, and *P* = 0.01).

The pooled analysis ([Figure 15](#fig15){ref-type="fig"}) of the 2 studies \[[@B41], [@B52]\] using Ichiro Fujishima Rating Scale (IFRS) showed no meaning with medium heterogeneity (*I*^2^ = 69%), neither the result of 2 studies \[[@B23], [@B42]\] using mini-nutritional assessment (MNA). Only one study \[[@B50]\] used Hamilton Depression Scale (HAMD), which showed that the depression degree of acupuncture group was lighter than the control group.

3.11. Blind Method Analysis {#sec3.11}
---------------------------

We extracted 7 studies using blind method from the enrolled studies, among which 4 studies used the clinical therapeutic efficiency and 5 used Watian Swallowing Test efficacy rate. There was no heterogeneity (*I*^2^ = 0%) after pooling them with dichotomous data and risk ratio (RR) ([Figure 16](#fig16){ref-type="fig"}). So the fixed effect model was used. The rectangle was on the right of equivalent line and the therapeutic efficiency of acupuncture group was 3.01 times as much as the control group. The result indicated that the acupuncture group could improve the therapeutic efficiency of dysphagia after stroke (RR = 3.01, 95% CI: 1.95 4.65, *Z* = 4.97, and *P* \< 0.00001).

Among the studies employing blind method, 4 of them used the SSA as the assessment indicator with continuous data and mean difference (MD). High heterogeneity was found after combined analysis. Sensitivity analysis revealed that heterogeneity might be due to the use of the test method and the gender imbalance in the clinical cases from one study \[[@B23]\]. The heterogeneity was lower (*I*^2^ = 21%) after removing it. We could see from the figure ([Figure 17](#fig17){ref-type="fig"}) that the rectangle was on the left of equivalent line, with a trend that acupuncture group could lower the SSA scores (MD = −4.47, 95% CI: −6.59 −3.36, *Z* = 7.85, and *P* \< 0.00001).

3.12. Adverse Reactions Report {#sec3.12}
------------------------------

Only 13 studies mentioned the security index, including how to prevent the subcutaneous hemorrhage, needle sickness, curved needle, broken needle, and the handing method during acupuncture process. Meanwhile, some studies reported the influence caused by the adverse reactions, not the others.

4. Discussion {#sec4}
=============

The study indicated that the therapeutic efficacy of acupuncture or acupuncture combined with other intervention was better than the control group, though some pooled results had higher heterogeneity. The interventions such as the acupuncture, rehabilitation training, and swallowing training were related to the professional skill of the practitioners, the same as the efficacy evaluation. Meanwhile, the various source of cases might lead to difference statistic results.

4.1. Comparison with Other Literatures {#sec4.1}
--------------------------------------

The acupuncture alone or combined with other interventions is widely used for dysphagia after stroke in China. There exists some evidence about the acupuncture for dysphagia after stoke. One report \[[@B88]\] stated although acupuncture had a tendency to improve dysphagia after stroke, it could not get the positive conclusion. There was report \[[@B89]\] which indicated that acupuncture combined with the swallowing rehabilitation training had certain advantage. Long and Wu \[[@B90]\] pointed out that acupuncture may be benefit for dysphagia, but high-quality research was needed. The present study reworked out inclusion and exclusion criteria to evaluate the efficacy of acupuncture for treatment of dysphagia after stroke and showed stronger evidence in the result.

4.2. Strengths and Limitations {#sec4.2}
------------------------------

In this paper, the studies included single blind method pooled to analysis alone and showed stronger evidence on acupuncture for treatment of dysphagia after stroke. We incorporated all researches in the past 5 years. Considering the clinical application of the intervention in this paper was special, such as the feeling of the patient. It was difficult to achieve true double blind. The studies using single blind method achieved the blind method to some extent. There was no or lower heterogeneity after combining.

On the outcome indicator of the dysphagia, most of the studies used the Watian Swallowing Test, SSA, Fujishima Rating Scale, and so on. Only 5 studies \[[@B18], [@B36], [@B45], [@B69], [@B46]\] used the golden standard-videofluoroscopy (VFSFF) \[[@B91]\] as the assessment indicator. The Watian Swallowing Test was put forward by the Toshio Watian from Japan, which was used as preliminary screening for dysphagia. Meanwhile, it was dependent on the feeling of patients and susceptible to them, which made the inconsistencies with most results in clinical and laboratory inspection \[[@B92], [@B93]\]. However, it was classified clearly and simply to use. So it was employed in many researches clinically \[[@B25], [@B18], [@B21]\]. Therefore, the choice of evaluation criteria needs to be more rigorous and scientific in the clinical trial design. In order to increase the reliability, high level evaluators should be chosen to evaluate the efficacy for dysphagia simultaneously.

However, there were several limitations of this review. Some research used the acupuncture combined with other interventions on the basic of the control group. And it was easily mixed with the effect of the acupuncture. Therefore, for experiment group, acupuncture alone or combined with the interventions of the control group might increase the reliability.

Some studies \[[@B94], [@B95]\] showed that acupuncture seemed to be safe in the subacute phase of ischemic stroke and cardiac arrhythmia. Others \[[@B96]\] indicated that the safety of acupuncture needs further evidence. And some researches \[[@B97], [@B98]\] show that the occurrence of the adverse events during acupuncture was closely related to the competency of the practitioners and the safety system of acupuncture. However, in the process of literature retrieval, we found that most of the literatures included in this paper paid too much attention to the validity of acupuncture and ignored the influence of adverse event during acupuncture. Therefore, we should consider the security issues in the research design. The unfinished trials caused by the security issues should be reported perfectly according to international standard \[[@B99]\] to ensure the data\'s integrity.

5. Conclusion {#sec5}
=============

In conclusion, acupuncture for dysphagia after stroke has therapeutic efficacy. And the acupuncture is safe and reliable within a certain range. More strict evaluation standard and high-quality RCT design are necessary for further exploration on the acupuncture for treatment of dysphagia after stroke.
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###### 

Retrieved literatures.

  Database   CNKI   WanFang   CSJD   CBM   PubMed   EMBASE   Cochrane   SCI
  ---------- ------ --------- ------ ----- -------- -------- ---------- -----
  Number     1361   1451      593    388   41       0        2          13

###### 

The basic characteristic of the included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                  Simple size \             Design/blind       Diagnostic criteria   Intervention     Control          Mean age (T/C)                Treatment course              Outcome measures
                                             T/C (M/F)                                                                                                                                                        
  ------------------------------------------ ------------------------- ------------------ --------------------- ---------------- ---------------- ----------------------------- ----------------------------- -----------------------------------
  Luo et al. \[[@B23]\] 2015                 33/29                     RCT/single blind   FNCOCD-1994           A + BT + RT      BT + RT          68.45 ± 9.73/66.90 ± 11.55    38.82 ± 48.77/27.14 ± 47.30   SSA + MNA

  Xia et al. \[[@B25]\] 2015                 62 (35/27)/62 (36/26)     RCT/single blind   NIHSS                 A + ST           ST               65.3 ± 14.2/66.1 ± 14.3       NR                            SSA + DOSS

  Xie et al. \[[@B17]\] 2011                 70 (39/31)/70 (28/32)     RCT/single blind   FNCOCD-1994           A                BT + RT          66.0 ± 8.4/68.4 ± 9.1         64.7 ± 32.0/60.0 ± 36.0       WST

  Yin et al. \[[@B22]\] 2011                 18 (10/8)/25 (11/9)       RCT/single blind   FNCOCD-1994           A + ST + ES      ST + ES          69.52 ± 6.01/65.41 ± 7.01     25.60 ± 3.09/24.32 ± 2.78     WST + IFRS

  Zhang et al. \[[@B18]\] 2014               29 (9/22)/31 (8/21)       RCT/single blind   RFNCOCD-1994          A + TCM + RT     BT + RT          65.55 ± 7.05/62.21 ± 8.37     42.56 ± 14.26/45.12 ± 12.56   VFSS + WST

  Wang \[[@B19]\] 2016                       30 (18/14)/30 (17/13)     RCT/single blind   RFNCOCD-1994          A + BT + ES      BT + RT          63.81 ± 8.445/64.87 ± 9.228   43.69 ± 18.39/42.0 ± 18.134   WST + SSA + SWAL-QOL

  Li and Bai \[[@B21]\] 2015                 32 (22/10)/30 (20/10)     RCT/single blind   RFNCOCD-1994          A + BT + RT      BT + RT          55.17 ± 4.73/54.97 ± 5.46     NR                            WST

  Liu \[[@B20]\] 2014                        34/34                     RCT/single blind   GFDTAISC-2010         A + BT + RT      BT               61.65 ± 8.253/63.71 ± 7.112   4.56 ± 4.294/4.18 ± 4.159     WST

  Hang et al. \[[@B24]\] 2014                39 (16/23)/39 (19/20)     RCT/single blind   RFNCOCD-1994          A + BT + OPT     BT               56.36 ± 10.55/56.36 ± 10.55   17.36 ± 15.52/19.49 ± 16.91   SSA

  Li et al. \[[@B26]\] 2009                  30/30 NR                  RCT/single blind   FNCOCD-1995           A + RT           RT               NR                            NR                            SSA

  Zhu et al. \[[@B27]\] 2012                 82 (59/23)/82 (53/29)     RCT/no blind       FNCOCD-1995           A + SUG          SUG              60.8/62.4                     NR                            WST + NIHSS + Barthel

  Chen and Zhang \[[@B28]\] 2016             30 (16/14)/30 (20/10)     RCT/no blind       CCDPATGBNBCMA-2007    A + RT           RT               61.63 ± 10.87/60.90 ± 10.53   47.68 d/41.63 d               WST

  Chen et al. \[[@B29]\] 2014                168 (117/5)/171 (131/4)   RCT/no blind       SOSNCOCD-2004         A + RT + BT      BT + RT          64.40 ± 11.20/64.05 ± 11.35   35.29 ± 32.84/33.12 ± 29.12   WST + TIFRS

  Wang \[[@B30]\] 2013                       30 (16/14)/30 (15/15)     RCT/no blind       FNCOCD-1996           A + BT + TCM     BT               65.3 ± 8.2/66.4 ± 5.4         14.98 ± 13.02/15.79 ± 13.76   SSA

  Duan \[[@B31]\] 2014                       40 (24/16)/40 (25/15)     RCT/no blind       FNCOCD-1994           A + SM + BT      BT               52.5 ± 3.7/52.5 ± 3.7         NR                            WST

  Bao and Zou \[[@B32]\] 2015                30 (21/9)/30 (22/8)       RCT/no blind       FNCOCD-1997           A + WM           WM               68.40 ± 7.166/68.77 ± 6.606   48.80 ± 23.57/50.03 ± 24.33   WST

  Fan et al. \[[@B82]\] 2007                 30 (13/17)/30 (14/16)     RCT/no blind       RFNCOCD-1996          A + WM           WM               67.76 ± 4.34/68.03 ± 4.05     46.37 ± 25.34/47.18 ± 26.15   WST

                                                                                                                                                                                                              

  Feng et al. \[[@B70]\] 2016                30 (18/12)/30 (19/11)     RCT/no blind       GFDTAISC-2010         A + RT + BT      BT + RT          60 ± 12/58 ± 22               38 ± 18/39 ± 18               WST + VFSS

  Zhen et al. \[[@B33]\] 2012                30 (16/14) 30 (13/17)     RCT/no blind       FNCOCD-1996           A + BT           BT               61 ± 3/60 ± 3                 7 d--10 m/6 d--10 m           WST

  Chang et al. \[[@B87]\] 2014               38 (27/11)/36 (28/8)      RCT/no blind       RFNCOCD-1996          A + ES + BT      ES + BT          46 ± 10/44 ± 11               16.6 ± 4.8/17.3 ± 5.2         IFRS

  Wu et al. \[[@B34]\] 2011                  80 (54/26)/75 (52/23)     RCT/no blind       TEESTCMDFS-1996       A + BT + ST      BT + ST          68/66                         NR                            WST

  Zhang and Yin \[[@B36]\] 2012              62 (32/30)/56 (22/34)     RCT/no blind       RFNCOCD-1995          A + BT + ST      BT + ST          70 ± 2/68 ± 2                 30.86 ± 12.72/31.78 ± 11.23   MBSAS + WST + DRS

  Chen \[[@B35]\] 2008                       30 (19/11)/30 (17/13)     RCT/no blind       TEESTCMDFS-1997       A + BT           BT               42--79/40--81                 NR                            WST

  Mao et al. \[[@B37]\] 2015                 40 (22/18)/40 (21/19)     RCT/no blind       FNCOCD-1995           A + RT + BT      RT + BT + SDTA   63.64/62.9                    56.2 ± 7.239/54.8 ± 6.033     VFSS

  Guo and Li \[[@B38]\] 2016                 40 (23/17)/40 (25/15)     RCT/no blind       FNCOCD-1997           A + BT           BT + ST          55.28 ± 10.34/56.12 ± 11.47   21.19 ± 8.28/20.49 ± 9.15     SSA

  Gao et al. \[[@B39]\] 2016                 40 (24/16)/40 (22/18)     RCT/no blind       FNCOCD-1994           A + ST           ST               57.8 ± 4.9/58.2 ± 5.1         NR                            WST

  Bai \[[@B40]\] 2016                        40 (16/24)/40 (15/25)     RCT/no blind       FNCOCD-1994           A + SDTA         SDTA             63.34 ± 9.04/63.15 ± 9.24     NR                            WST

  Song \[[@B41]\] 2012                       30 (19/11)/30 (20/10)     RCT/no blind       CCDPATGBNBCMAG-2005   A + ST + BT      ST + BT          61.3/61.52                    2.26 m/2.09 m                 WST + IFRS

  Zhou et al. \[[@B42]\] 2014                30 (19/11)/30 (20/10)     RCT/no blind       CCDPATGBNBCMA-2005    A                RT               65.63 ± 9.33/64.35 ± 8.26     NR                            WST + MNA + Barthel

  Liu \[[@B72]\] 2014                        45 (28/17)/42 (27/15)     RCT/no blind       FNCOCD-1996           A + ST           ST               52.3 ± 8.7/53.6 ± 8.5         NR                            WST

  Li et al. \[[@B54]\] 2013                  30 (20/10)/30 (21/9)      RCT/no blind       FNCOCD-1996           A + BT + ST      BT               56.9 ± 4.6/57.1 ± 3.7         NR                            WST

  Wang \[[@B43]\] 2011                       30 (18/12)/30 (16/14)     RCT/no blind       FNCOCD-1995           A + BT           BT               56.5/56.8                     6--35 d/7--34 d               WST

  Liu and Zheng \[[@B44]\] 2014              33 (17/16)/31 (14/17)     RCT/no blind       FNCOCD-1996           A + BT           BT               61.7/59.8                     NR                            WST

  Gu \[[@B45]\] 2011                         35 (22/13)/35 (23/12)     RCT/no blind       FNCOCD-1996           A + RT + BT      BT + RT          71.98 ± 10.19/70.74 ± 11.58   14.69 ± 15.76/17.11 ± 15.52   CT7R

  Gao et al. \[[@B48]\] 2014                 52 (31/21)/49 (27/22)     RCT/no blind       CCDPATGBNBCMA-2007    A + BT + SDTA    BT + SDTA        60.25 ± 8.36/61.37 ± 7.36     NR                            WST

  Chen \[[@B47]\] 2016                       30 (17/13)/30 (18/12)     RCT/no blind       FNCOCD-1995           A + BT + RT      BT + RT          62.90 ± 10.04/63 ± 9.83       NR                            VFSS + Rosenbek

  Ruan et al. \[[@B49]\] 2015                25 (12/13)/25 (14/11)     RCT/no blind       CCDPATGBNBCMA-2005    A + BT + ST      BT + ST          58.01 ± 10.74/57.98 ± 11.82   47.02 ± 7.47/46.87 ± 6.96     IFRS

                                                                                                                                                                                                              

  Wang \[[@B50]\] 2015                       46 (35/11)/45 (31/14)     RCT/no blind       FNCOCD-1997           A + BT           RT + BT          61 ± 10/64 ± 10               54.63 ± 27.18/51.93 ± 23.10   WST + SSA + SWAL-QOL + HAMD + MBI

  Li et al. \[[@B51]\] 2015                  65 (47/18)/65 (49/16)     RCT/no blind       FNCOCD-1996           A + BT           BT               63.87 ± 5.24/63.96 ± 5.33     2.32 ± 1.79/3.38 ± 1.90       WST + IFRS

  Zhang et al. \[[@B52]\] 2011               30/30                     RCT/no blind       FNCOCD-1995           A + ST           ST               NR                            NR                            WST

  Qu \[[@B53]\] 2009                         30 (17/13)/30 (18/12)     RCT/no blind       FNCOCD-1997           A + RT           RT               69.06 ± 6.67/66.84 ± 10.39    27.27 ± 13.76/27.30 ± 8.11    WST

  Chen and Lin \[[@B55]\] 2016               60 (38/22)/60 (41/19)     RCT/no blind       RFNCOCD-1996          A + RT           RT               65/63                         9--40 d/10--38 d              WST

  Gao and Zhu \[[@B56]\] 2015                30/30 (30/30)             RCT/no blind       FNCOCD-1996           A + BT           BT               45--75                        5--45 d                       WST

  Liu et al. \[[@B57]\] 2012                 36 (22/14)/36 (25/11)     RCT/no blind       FNCOCD-1994           A + BT           BT               57.6 ± 8.2/58.5 ± 8.7         35.4 ± 6.5/34.8 ± 7.1         WST

  Dong et al. \[[@B58]\] 2014                30 (16/14)/30 (17/13)     RCT/no blind       FNCOCD-1995           A + RT           RT               63/62                         35/36                         WST

  Zhang \[[@B59]\] 2014                      50 (28/22)/46 (26/20)     RCT/no blind       FNCOCD-1996           A + BT + NEST    RB + BT          67.5 ± 7.2/68.2 ± 6.4         8.8 ± 1.2/9.6 ± 1.4           WST

  Li et al. \[[@B60]\] 2014                  20 (11/9)/20 (12/8)       RCT/no blind       FNCOCD-1995           A + BT + ST +    BT + ST          60.4 ± 4.6/61.3 ± 4.2         15.3 ± 2.7/14.7 ± 2.1         WST + OFS

  Wang and Yang \[[@B61]\] 2013              45 (20/25)/45 (21/24)     RCT/no blind       FNCOCD-1995           A + ST + BT      ST + BT          61.33 ± 4.19/61.61 ± 5.34     29.12 ± 7.09/31.41 ± 6.32     WST

  Ding and Zhang \[[@B62]\] 2013             30 (17/13)/30 (19/11)     RCT/no blind       FNCOCD-1994           A + BT           BT               63.14 ± 7.28/62.47 ± 6.91     27.2 ± 7.5/28.6 ± 7.9         WST

  Fang \[[@B63]\] 2014                       30 (16/14)/30 (15/15)     RCT/no blind       FNCOCD-1996           A + BT + CMPPS   BT + ST          52.8 ± 6.9/53.9 ± 6.0         34.1 ± 15.3/31.4 ± 12.6       WST

  Qin \[[@B64]\] 2015                        30 (26/4)/30 (21/9)       RCT/no blind       RFNCOCD-1995          A + BT           RT + BT          61.42 ± 13.65/63.86 ± 10.83   34.99 ± 8.75/31.18 ± 7.21     WST + SSA + ADL

  S. Zhang and G. M. Zhang \[[@B65]\] 2014   87 (64/23)/87 (58/29)     RCT/no blind       CCDPATGBNBCMA-2007    A + RT           RT               63.86 ± 10.55/64.61 ± 9.70    28.45 ± 23.42/31.48 ± 27.80   WST + IFRS

  Zhu and Zhao \[[@B66]\] 2015               30 (18/12)/30 (16/14)     RCT/no blind       TEESTCMDFS-1996       A + BT           RT               53.60 ± 12.96/56.10 ± 10.81   6.83 ± 1.60/7.05 ± 1.33       WST

  Fu \[[@B67]\] 2016                         53 (30/23)/48 (28/20)     RCT/no blind       FNCOCD-2007           A + RT + BT      RT + BT          52.8 ± 10.4/55.4 ± 13.8       6.8 ± 2.3/8.5 ± 3.1           SSA + SWAL-QOL

  Zhang et al. \[[@B68]\] 2007               110 (67/43)/110 (62/48)   RCT/no blind       RFNCOCD-1995          A + RT           RT               53.16 ± 6.84/51.37 ± 8.63     NR                            WST

  Wei and An \[[@B69]\] 2012                 50 (34/16)/50 (36/14)     RCT/no blind       CCDPATGBNBCMA-2005    A + BT + RT      BT               57.8/57.7                     3--45/4--46                   WST

  Yin \[[@B71]\] 2013                        57 (32/25)/56 (30/26)     RCT/no blind       RFNCOCD-1996          A + RT + BT      RT + BT          62.5 ± 6.5/60.8 ± 7.4         11.5 ± 2.2/10.3 ± 1.3         SSA + SWAL-QOL

                                                                                                                                                                                                              

  Huang et al. \[[@B73]\] 2011               28 (16/12)/28 (15/13)     RCT/no blind       FNCOCD-1995           A + RT           RT               38--75/38--73                 15 d--6 m/18 d/5 m            WST

  Chen et al. \[[@B74]\] 2011                28 (12/16)/28 (13/15)     RCT/no blind       FNCOCD-1995           A + ST + NEST    ST               57.71 ± 9.17/59.50 ± 8.79     50.21 ± 21.59/49.14 ± 20.76   WST

  Wang and Cui \[[@B75]\] 2011               70 (49/12)/70 (52/18)     RCT/no blind       FNCOCD-1996           A + LFPT + BT    BT               66.12/64.87                   65.4/71.1                     WST

  Li \[[@B76]\] 2016                         36 (23/13)/36 (24/12)     RCT/no blind       FNCOCD-1997           A + BT + AM      BT               52.98 ± 4.93/53.61 ± 4.81     13.65 ± 5.25/12.53 ± 6.16     WST

  Yi \[[@B77]\] 2014                         30 (19/11)/30 (18/12)     RCT/no blind       CCDPATGBNBCMA-2010    A + SUMM         SUMM             62.03 ± 10.14/63.90 ± 8.64    66.23 ± 47.94/70.23 ± 44.36   SSA + ADL

  Jia et al. \[[@B78]\] 2014                 30 (23/7)/30 (21/9)       RCT/no blind       FNCOCD-1995           A + RT           RT               58.30 ± 7.87/56.47 ± 8.43     \<6 M                         WST

  Huang et al. \[[@B79]\] 2013               30 (17/13)/30 (16/14)     RCT/no blind       FNCOCD-1995           A                TCM              65 ± 3/67 ± 2                 109 ± 4/108/9                 WST

  Feng and Sun 2016 \[[@B80]\]               30/30                     RCT/no blind       FNCOCD-1996           A                BT               NR                            NR                            WST

  Chen et al. \[[@B81]\] 2015                30/30                     RCT/no blind       FNCOCD 1995           A + BT + ST      BT + ST          NR                            NR                            IFRS

  Feng et al. \[[@B83]\] 2015                45 (32/13)/45 (29/16)     RCT/no blind       FNCOCD-1995           A + BT + LFES    LFES + BT        63.12/52.36                   56.52/45.12                   WST

  Yu and Hu \[[@B84]\] 2012                  40 (23/17)/38 (20/18)     RCT/no blind       FNCOCD-1995           A + RT + BT      RT + BT          62.51 ± 10.17/62.51 ± 10.17   13.78 ± 2.62/14.56 ± 2.48     WST

  Zhao and Zhang \[[@B85]\] 2012             94 (48/46)/92 (47/45)     RCT/no blind       FNCOCD-1995           A + STA          STA              59.78/60.03                   NR                            WST

  Yu et al. \[[@B86]\] 2012                  30 (19/11)/30 (13/17)     RCT/no blind       FNCOCD-1995           A + BT           BT               54.30 ± 11.5/55.50 ± 10.7     30.25 ± 10.53/31.12 ± 8.92    WST

  Zheng \[[@B46]\] 2014                      30 (21/9)/30 (23/7)       RCT/no blind       FNCOCD-1994           A + ST           ST               68.3 ± 13.84/70.26 ± 11.97    43.37 ± 24.37/44.30 ± 22.52   CT7R + SSA + VFSS + WST
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\(1\) Diagnosis: FNCOCD, the diagnostic criterion of the Fourth National Conference on cerebrovascular diseases in 1994 or the revised diagnostic criterion in 1995 or 1996; FNCOCD the revised diagnostic criterion in 1995 or 1996; CCDPATGBNBCMA, the "Chinese Cerebrovascular Disease Prevention And Treatment Guidelines (Try Out)" established by Neurology Branch of Chinese Medical Association according to the 2005 or 2007 Disease Control Division; GFDTAISC2010, the guidelines for diagnosis and treatment of acute ischemic stroke in China 2010 Edition; NIHSS, National Institutes of Health Stroke Scale; TEESTCMDFS, the therapeutic effect evaluation standard of TCM diagnosis for stroke; SOSNCOCD, summary of the Sixth National Conference on cerebrovascular diseases. (2) Measures: CT7R, Caiteng 7 Rank; MBSAT, medical bedside swallowing assessment scale; DRS, dysphagia rank scale; WST, Watian Swallowing Test; SSA, standard swallowing assessment; VFSS, videofluoroscopy; IFRS, Ichiro Fujishima Rating Scale; ADL, Activity of Daily Life; WALQOL, Swallowing-Related Quality of Life; DSS, dysphagia severity scale; OFS, oral function score. (3) Intervention: SM, swallowing mixture; A, acupuncture; RT, rehabilitation; BT, basic treatment; SUMM, stroke unit management model; ST, swallowing treatment; SUG, stroke unit group; ES, electrical stimulation; TCM, traditional Chinese medicine; WM, Western medicine; OPT, oral positioning therapy; AM, acupoint massage; NEST, neuromuscular electrical stimulation; MS, muscle electrical stimulation; LPT, low frequency pulse electrotherapy; ES, electrical stimulation; SDTA, swallowing disorder therapeutic apparatus; CMPPS, cold medicine Popsicle pharyngeal stimulation; IS, ice stimulation; NR, no report.

[^1]: Academic Editor: Ching-Liang Hsieh
